AVLN - CIK 0001540171
Avalyn Pharma Inc. trades as AVLN and has a market capitalization of $1.20 B, making it the #2504 largest US-listed company by market value. This page tracks Avalyn Pharma Inc. through 51 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13D | - | 2026-05-08 |
| SCHEDULE 13D | - | 2026-05-08 |
| SCHEDULE 13G | - | 2026-05-07 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| SCHEDULE 13G | - | 2026-05-05 |
| Insider trade | 4 | 2026-05-04 |
| Insider trade | 4 | 2026-05-01 |
Access to the live webcast of this event, and the archived recording, will be posted under the News & Events page of the Investor section of the company’s website at https://investors.avalynpharma.com/
Updated findings from the ATLAS open-label extension trial will highlight the long-term tolerability profile of AP01 (inhaled pirfenidone) among the cohort of patients with progressive pulmonary fibrosis at up to four years of treatment. See the EULAR online program for more details. The presentation will also be accessible on the company’s website .
“Our presentations at ATS reflect a core belief at Avalyn - that patients should help shape the therapies designed to serve them,” said Lyn Baranowski, CEO of Avalyn Pharma. “By focusing on inhaled approaches and integrating patient and caregiver input early in development, we aim to better understand and improve how therapies are used and experienced in the real-world, not just in clinical trials. We believe this approach is critical to providing the highest care for patients living with pulmonary fibrosis and empowering the pulmonary fibrosis community.”
The largest companies sharing Avalyn Pharma Inc.'s SEC industry classification (pharmaceutical preparations).
Avalyn Pharma Inc. (AVLN) has a market capitalization of $1.20 B as of 2026-05-29, ranking #2504 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.